A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Public ClinicalTrials.gov record NCT07216703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Study identification
- NCT ID
- NCT07216703
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,023 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Sacituzumab Tirumotecan Biological
- Bevacizumab Biological
- Paclitaxel Drug
- Cisplatin Drug
- Carboplatin Drug
- Rescue Medications Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2026 (Actual)
- Primary completion
- Oct 29, 2031 (Estimated)
- Completion
- Oct 29, 2031 (Estimated)
- Last update posted
- Oct 13, 2026
2026 – 2031
United States locations
- U.S. sites
- 30
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama- Birmingham ( Site 5015) | Birmingham | Alabama | 35294 | Recruiting |
| Alaska Womens Cancer Care ( Site 5046) | Anchorage | Alaska | 99508 | Recruiting |
| CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037) | Irvine | California | 92612 | Recruiting |
| University of California Irvine Medical Center ( Site 6006) | Orange | California | 92868 | Recruiting |
| Florida Cancer Specialists - South ( Site 7001) | Fort Myers | Florida | 33901 | Recruiting |
| Mount Sinai Braman Comprehensive Cancer Center ( Site 5043) | Miami Beach | Florida | 33140 | Recruiting |
| Mount Sinai Comprehensive Cancer Center ( Site 6000) | Miami Beach | Florida | 33140 | Recruiting |
| Florida Cancer Specialists - East ( Site 7000) | West Palm Beach | Florida | 33401 | Recruiting |
| Winship Cancer Institute of Emory University ( Site 5005) | Atlanta | Georgia | 30308 | Recruiting |
| Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005) | Savannah | Georgia | 31405 | Recruiting |
| TRIALS 365 ( Site 6008) | Shreveport | Louisiana | 71103 | Recruiting |
| Maryland Oncology Hematology (MOH) ( Site 8001) | Columbia | Maryland | 21044 | Recruiting |
| Minnesota Oncology Hematology, PA ( Site 8003) | Edina | Minnesota | 55435 | Recruiting |
| Women's Cancer Center of Nevada ( Site 6011) | Las Vegas | Nevada | 89106 | Recruiting |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5039) | Mineola | New York | 11501 | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) | New York | New York | 10016 | Recruiting |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6002) | Columbus | Ohio | 43210 | Recruiting |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001) | Tulsa | Oklahoma | 74146 | Recruiting |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) | Eugene | Oregon | 97401 | Recruiting |
| Honickman Center ( Site 5033) | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Asplundh Cancer Pavilion ( Site 5002) | Willow Grove | Pennsylvania | 19090 | Recruiting |
| Women & Infants Hospital ( Site 6003) | Providence | Rhode Island | 02905 | Recruiting |
| University of Tennessee Medical Center ( Site 6012) | Knoxville | Tennessee | 37920 | Recruiting |
| Texas Oncology - DFW ( Site 8005) | Fort Worth | Texas | 76104 | Recruiting |
| Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010) | Houston | Texas | 77030 | Recruiting |
| Texas Oncology-The Woodlands ( Site 8000) | The Woodlands | Texas | 77380 | Recruiting |
| Texas Oncology - Northeast Texas ( Site 8002) | Tyler | Texas | 75702 | Recruiting |
| University of Virginia Cancer Center ( Site 5044) | Charlottesville | Virginia | 22908 | Recruiting |
| University of Virginia Cancer Center ( Site 6014) | Charlottesville | Virginia | 22908 | Recruiting |
| Inova Schar Cancer Institute ( Site 5045) | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07216703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07216703 live on ClinicalTrials.gov.